Medigus Filed a $3 Million Buyback Program
December 01 2021 - 7:15AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, today announced it had
filed a motion seeking a court approval for a capital reduction of
up to $3 million for the Company's buyback program, increasing the
contemplated program from $2 million to $3 million.
Contingent upon court’s approval the buyback
program will initiate during the first quarter of 2022.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technology company focused on innovative growth partnerships,
mainly in advanced medical solutions, digital commerce and electric
vehicle markets. Medigus' affiliations in the medical solutions
arena include ownership in Polyzion Ltd. and ownership in industry
4.0 company, ScoutCam Inc. The Company’s affiliates in digital
commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer
Technologies Ltd. In the electric vehicle market, Charging Robotics
Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of
technology solution providers. To learn more about Medigus’
advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. Because such statements deal with
future events and are based on Medigus’ current expectations, they
are subject to various risks and uncertainties, and actual results,
performance or achievements of Medigus could differ materially from
those described in or implied by the statements in this press
release. More specifically, Medigus’ motion may not be approved for
the full amount requested or at all. Medigus' failure in
whole or in part to obtain the request for approval from the
Israeli court could prevent or reduce the Company’s ability to
buyback its shares.
The forward-looking statements contained or
implied in this press release are subject to other risks and
uncertainties, including those discussed in any filings with the
Securities and Exchange Commission (“SEC”). Except as otherwise
required by law, Medigus undertakes no obligation to publicly
release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. References and links to
websites have been provided as a convenience, and the information
contained on such websites is not incorporated by reference into
this press release. Medigus is not responsible for the contents of
third-party website.
Company Contact: Tali DinarChief Financial
Officer+972-8-6466-880ir@medigus.com
Investor Relations Contact:Miri SegalCEOMS-IR
LLC+1-917-607-8654msegal@ms-ir.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2024 to May 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From May 2023 to May 2024